Prognosis is poor for patients with biologically aggressive Non-Hodgkin lymphoma (NHL), refractory to chemotherapy or relapsed after autologous transplantation, especially when no disease control before allogeneic transplantation is achieved. In 16 patients (median age 53, median prior regimes 5) with relapsed or refractory non-remission NHL, we analysed retrospectively the efficacy of a sequential therapy comprising clofarabine re-induction followed by a reduced-intensity conditioning with fludarabine, CY and melphalan, and T-cell-replete HLA-haploidentical transplantation. High-dose CY was utilized post-transplantation. All patients engrafted. Early response (day +30) was achieved in 94%. Treatment-related grade III-IV toxicity occurred in 56%, most commonly transient elevation of transaminases (36%), while there was a low incidence of infections (19% CMV reactivation, 19% invasive fungal infection) and GVHD (GVHD: acute III-IV: 6%; mild chronic: 25%). One-year non-relapse mortality was 19%. After a median follow-up of 21 months, estimated 1-and 2-year PFS was 56 and 50%, respectively, with 11 patients (69%) still alive after 2 years. In summary, sequential therapy is feasible and effective and provides an acceptable toxicity profile in high-risk non-remission NHL. Presumably, cytotoxic reinduction with clofarabine provides enough remission time for the graft-versus lymphoma effect of HLA-haploidentical transplantation to kick in, even in lymphomas that are otherwise chemo-refractory.
INTRODUCTION
Allogeneic haematopoietic SCT (allo-HSCT) has become a valuable option as a potentially curative salvage treatment for patients with relapsed lymphoma. 1 Successful use of reduced-intensity conditioning (RIC) regimens and encouraging outcomes mediated by a putative graft-versus lymphoma (GVL) effect 2 have underlined the value of allo-HSCT in Non-Hodgkin lymphoma (NHL). Still, patients with advanced, aggressive lymphoma achieving no remission before allo-HSCT or suffering from relapse after autologous transplantation, or both, have a poor prognosis. Data on these patients are limited, 3, 4 and new treatment strategies are required. To enhance the anti-lymphoma effect in patients with nonremission NHL, we introduced the concept of sequential therapy, as previously described by Schmid et al. 5, 6 for acute myeloid leukaemia, combining clofarabine with HLA-haploidentical haematopoietic SCT (haplo-HSCT). An additive a GVL effect mediated by HLA disparity is presumed. 7, 8 Clofarabine has shown significant anti-tumour activity as a single agent in the treatment of NHL, including rituximabrefractory patients, 9, 10 and was feasible and effective in HLA-matched and mismatched allo-HSCT. [11] [12] [13] [14] Furthermore, T-cell-replete HLA-haploidentical transplantation using high-dose CY for post-grafting immunosuppression is reported to be associated with low rates of non-relapse mortality (NRM), and favourable results in the treatment of lymphoma have been observed. 8, 15, 16 Therefore, sequential therapy comprising clofarabine and T-cell-replete HLA-haploidentical transplantation seemed to be an attractive concept in the treatment of advanced NHL.
Here, we report on the outcome of the first 16 adults suffering from relapsed and/or refractory non-remission NHL undergoing this sequential therapy at our institution.
PATIENTS AND METHODS
Data of all patients with aggressive NHL who received sequential HLAhaploidentical transplantation between September 2010 and February 2013 were included in this retrospective analysis. Patients with (1) age ⩾ 18 years, (2) ECOG score ⩽ 1, (3) adequate renal and hepatic function (creatinine clearance over 70 mL/min; serum bilirubino1.5 ULN, GOT/GPTo2.5 ULN) were considered for sequential therapy. All patients lacked a suitable HLAmatched donor. Patients gave written informed consent in accordance with the modified Helsinki declaration. Patients who were ineligible for autologous transplantation, or had failed such treatment, were included, as well as patients with non-remission disease status or chemo-refractory disease. who shared at least one HLA haplotype with the patient, while showing negative serum samples for donor-specific anti-HLA antibodies, were considered, with a preference for CMV-and ABO-matched donors.
Preparative regimen, stem cell source and GVHD prophylaxis According to the concept of sequential therapy in acute leukaemia, 5,12 the preparative regimen consisted of an induction chemotherapy with clofarabine (30 mg/m 2 IV over 5 days) followed, after 3 days of rest, by RIC (CY 14.5 mg/kg IV per day on 2 days, fludarabine 30 mg/m 2 IV per day on 5 days and melphalan 110 mg/m 2 IV on 1 day) for T-cell-replete HLAhaploidentical transplantation. Unstimulated and unmanipulated bone marrow was the preferred graft source, and high-dose CY post transplantation was used as a backbone for prophylaxis of rejection and GVHD. 15 G-CSF was routinely administered starting on day +5 until neutrophil engraftment. No rituximab was used during the preparative regimen. The treatment schedule is shown in detail in Figure 1 .
Definition of disease response
Disease was defined as chemo-refractory at the time of haplo-HSCT when less than a PR or stable disease was achieved by the most recent chemotherapy or progression was observed during chemotherapy or in the first 4 weeks thereafter. Disease response was retrospectively evaluated according to the standards of an international workshop to standardize response criteria for NHLs. 17 Engraftment, chimerism, GVHD, infection and toxicity Engraftment was confirmed by analysis of chimerism, which was performed using the FISH technique in a sex-different and the STR technique in a sex-matched setting.
Diagnosis and clinical grading of acute and chronic GVHD and invasive fungal infection were assessed utilizing standard definitions, [18] [19] [20] and nonhaematological toxicity was graded according to the recorded National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE v3.0) from the initiation of the sequential therapy until day +30 after transplantation.
Supportive care
Patients were accommodated in high-efficiency particulate air (HEPA)-filtered, single rooms. Local standard anti-microbiological prophylaxis with acyclovir and trimethoprim-sulfamethoxazole was applied. Antifungal prophylaxis consisted of either azoles or echinocandins. Patients were screened weekly for CMV and EBV reactivation (PCR). They were treated pre-emptively with ganciclovir or foscarnet in the case of CMV reactivation, and with cidofovir or rituximab, or both, in the case of EBV reactivation. If possible, hepatotoxic and nephrotoxic drugs such as azoles, liposomal amphothericin B, cotrimoxazole and aminoglycosides were avoided on the days of clofarabine infusion. Prophylaxis of veno-occlusive disease was performed with continuous infusion of low-dose unfractionated heparin and orally applied ursodeoxycholic acid. High-dose CY was administered IV over 1 h together with IV mesna for prophylaxis of haemorrhagic cystitis.
Statistics
Patients were first evaluated for engraftment, rejection, GVHD, infection, toxicity and early (day +30) or later response (day +100; day +360) by means of summary statistics. Second, analysis of estimated PFS and OS was performed by means of the Kaplan-Meier method using SAS 9.3. (SAS Institute,Cary, NC, USA). OS was calculated from the day of transplantation (day 0) until death. PFS was calculated from the day of transplantation until death or detection of progressive disease. The cumulative incidence of NRM was calculated to take account of the presence of competing risks using the R package 'cmpskr' as described. 21 
RESULTS
We evaluated the course of 16 adult patients (five female; median age 53 years; median HCT-comorbidity index 3 22 ) suffering from aggressive B-or T-cell NHL (mantle cell lymphoma (n = 7), angioimmunoblastic T-cell lymphoma (n = 2), B-lymphoblastic lymphoma (n = 1), diffuse large cell B-cell lymphoma (DLBCL; n = 1) and secondary DLBCL (n = 5)) who were consecutively transplanted at our institution between September 2010 and February 2013. Median donor age was 39 years, nine donors were female. All donor/recipient pairs were mismatched for at least four HLAloci. Three donor/recipient pairs showed a high-risk constellation for CMV reactivation. 23 Patients' and donors' characteristics are provided in Table 1 .
Disease status at haplo-HSCT The median number of immuno-chemotherapy regimens before haplo-HSCT was 5 (range 1-8). A relapse after autologous transplantation was observed in 8 patients (50%). No patient was in CR before sequential therapy. Disease status at haplo-HSCT was disease progression, stable disease and PR in 11 (69%), 1 (6%) and 4 (25%) patients, respectively. Chemo-refractory disease was stated in 11 patients (69%), and a p53 deletion in 2 patients. Details of disease status are shown in Table 1 .
Sequential therapy regimen All patients received clofarabine followed after 3 days of rest by RIC with fludarabine and cyclophosphamide plus melphalan. An unmanipulated T-cell-replete graft was given on day 0 (unstimulated (no G-GSF) bone marrow n = 14; G-CSF-mobilized peripheral blood stem cells n = 2). The median cell dose of the BM graft was 2.73 (range 1.26-4.35) nuclleated cells × 10 8 /kg body weight of the recipient (Table 1) . GVHD-prophylaxis consisted of high-dose CY post transplant on day +3 and +4 (50 mg/kg IV; each day) followed by tacrolimus IV (targeted levels 8-12 ng/L) and mycophenolate mofetil IV (MMF 4 × 500 mg), both starting on day +5. 15 In the absence of GVHD, MMF was stopped on day +35, and tacrolimus was discontinued before day +180 (Figure 1 
Engraftment and rejection
No primary graft rejection occurred. Median time to neutrophil engraftment, which was achieved in all patients, was 19 days (range 14-36). Platelet engraftment was achieved in 14 patients (88%) within a median of 30 days (range 18-115) (Figure 2) . By day +100, one patient had died from lymphoma and one patient had died of toxicity. Among the 14 remaining patients, 13 had maintained full donor chimerism until day+100, while one patient showed mixed chimerism (o 90% donor cells).
GVHD
Acute GvHD grade I (n = 4; 25%), grade II (n = 5; 31%) and III (n = 1; 6%) occurred in 10 patients (Table 1) with skin being the most frequently involved organ (n = 10). Only two patients showed concomitant liver GVHD. Three organs (skin, liver and gut) were affected in one patient with low compliance for taking oral medication. No patient developed grade IV acute GVHD. For first line treatment of acute GVHD, five patients received high-dose steroids at a dose of ⩾ 2 mg/kg. One patient with grade III acute GVHD required second-line immunosuppressive therapy with etanercept. Mild chronic GVHD was observed in 4 patients (25%). Median time to onset of acute GVHD was 27 days (range , and 142 days to chronic GVHD (range 113-516).
Toxicity and infection Treatment-related non-haematological toxicity ⩾ grade III occurred in 9 patients (56%) with transient elevation of liver enzymes (n = 6; 38%), mucositis (n = 3; 19%) and nausea and vomiting (n = 3; 19%) as the most commonly seen severe toxicities, while hand-foot syndrome (n = 1; 6%), haemorrhagic cystitis (HC; n = 1; 6%) and creatinine elevation (n = 1; 6%) were rare as severe complications (Table 2) . No haemodialysis was required, and no veno-occlusive disease was observed.
Under antifungal prophylaxis, only two patients fulfilled the criteria for probable invasive aspergillosis (pulmonary), and only one patient was diagnosed with fungaemia (candida parapsilosis). CMV reactivation was observed in 3 patients (19%), and EBV reactivated in 1 (6%), but no patient developed CMV disease or post-transplantation lympho-proliferative disorder. No adenovirus infection was observed, one patient developed respiratory syncytial virus pneumonia. This patient required mechanical ventilation due to toxic lung failure, and the outcome was fatal.
Five patients suffered from haemorrhagic cystitis (HC; grade II-IV). Four of these patients showed more than 1 million copies of concomitant BK and JC polyomavirus in their urine. Plasma BK virus polymerase chain reaction was positive in 3 of 5 patients with HC, suggesting an additional polyomavirus-associated nephropathy.
Disease response Early response (day +30) was achieved in 94% (15 patients; CR n = 4; PR n = 11), whereas only one patient showed disease progression. Remission status improved in six patients (five chemo-refractory) within the first 3 months after haplo-HSCT without further therapy. In particular, early response was observed in 91% of chemo-refractory patients (10 out of 11; CR n = 2; PR n = 8) including 7 out of 8 patients who had relapsed after autologous transplantation. At day +100, five PRs of chemorefractory patients improved to CRs (three patients with failure after autologous transplantation), and at day +360 two more patients' remission status improved to CR (one with chemorefractory disease and failure after a prior autologous transplantation). Overall, only 36% (4 out of 11) of the chemo-refractory patients relapsed, including two patients who had relapsed after autologous transplantation. Information about the course of response is given in Table 3 . Abbreviations: AILT = angioimmunoblastic T-cell lymphoma; ASCT = autologous SCT; B-LBL = B-cell lymphoblastic lymphoma; DLBCL = diffuse large B-cell lymphoma; HCI = haematopoietic cell transplantation-comorbidity index; MCL = mantle cell lymphoma; NA = not applicable; NCs = nucleated cells; No. = number; SD = stable disease; sDLBCL = secondary transformed DLBCL. In two of the relapsed patients it was possible to perform DLI, which again induced a remission (one PR, one CR) in both patients. Initial cell dose of DLI was 1 × 10 5 CD3+ cells/kg, and maximum dose was 5 × 10 6 CD3+ cells/kg. In the absence of GVHD, DLI cell dose was escalated in four steps with an increase of 0.5 × 10 5 CD3+ cells/kg per each at a 4-to 6-week interval. Patients received their first dose of DLI on day+219 and day +415 after haplo-HSCT.
Survival and non-relapse mortality After a median follow-up of 21.1 months (range 12.1-41.2), four patients had relapsed and one patient showed persistent disease, while five patients had died (disease-related n = 2; treatment related n = 3). Cumulative incidence of NRM was 0% at day +90 and 18.75% (95% confidence interval (CI); 4.3-41.1) at 1 year after haplo-HSCT, respectively. Causes of NRM were cerebral bleeding in one patient (day +101), and toxicity/infection in two patients (day +141; day +156), both with p53 deletion positive MCL. Estimated 1-and 2-year PFS survival was 56.2% (95% CI: 29.6-76.2) and 50% (95% CI: 24.6-71.0), respectively. Estimated OS at 1 and 2 years after haplo-HSCT was 68.8% (95% CI: 40.5-85.6) each. Survival curves (PFS, OS) are shown in Figure 3 .
DISCUSSION
Scarce data exist about the benefit of allogeneic transplantation in the treatment of patients with aggressive lymphoma who present with active relapsed/chemo-refractory disease at the time of transplant. 24 In this grave situation, no standard treatment is available. As a treatment attempt, we performed a sequential therapy comprising re-induction chemotherapy with clofarabine followed by T-cell-replete HLA-haploidentical transplantation. This approach proved feasible and safe and was well-tolerated with a 1-year NRM of 19%. A high rate of early response (94%) was induced. Given the patients' high-risk profiles, a favourable efficacy was demonstrated by a 1-and 2-year PFS of 56 and 50%, respectively. This sequential T-cell-replete haploidentical approach using high-dose CY in a narrow time-window after transplantation for in vivo depletion of allo-reactive T cells 15, 25, 26 demonstrated a sufficient immunosuppressive potential with few side effects as evidenced by the absence of graft rejection, while rates of severe GVHD (acute grade III-IV: 6%; 25% mild chronic) were low in comparison with HLA-matched non-myeloablative allo-HSCT in lymphoid malignancies. 1, 27, 28 Embedding clofarabine in a sequential therapy concept for haplo-HSCT in non-remission lymphoma does not result in increased toxicity. In contrast to HLA-matched transplantation administering clofarabine immediately after BU for conditioning in patients with non-remission malignant haematological diseases, 11 severe toxicities were less common, but are comparable to those of the T-cell-replete sequential therapy haplo-approach in nonremission acute leukaemia. 12 NRM was acceptable and in the lower end of the range (15-41%) described for RIC HLA-matched 3,29-34 and T-cell-replete haplo-HSCT performed mostly in chemo-sensitive, less aggressive lymphoma without active disease at the time of transplant. 15, 32 There is some evidence of a GVL effect after RIC transplantation in aggressive NHL, 2, 4, 24, 32 but this effect can take several months to become apparent. 35 Unfortunately, high-risk NHL patients either being chemo-resistant or achieving no CR before allo-HSCT frequently present with disease progression before a durable control mediated through the immune-competent cells of the allogeneic graft can be established. [36] [37] [38] This highlights the importance of early disease control. We found that early disease control (day +30) was highly effective after sequential therapy, which is demonstrated by the response rate of 94% for the entire cohort and 91% for chemo-refractory disease. Strikingly, response rates compare favourably with HLA-matched transplantation not following this strategy. 4, 34 It is notable that the remission status Abbreviations: AILT = angioimmunoblastic T-cell lymphoma; ASCT = autologous SCT; B-LBL = B-cell lymphoblastic lymphoma; DLBCL = diffuse large B-cell lymphoma; MCL = mantle cell lymphoma; NR = not reached; PD = disease progression; SD = stable disease; sDLBCL = secondary transformed DLBCL.
Sequential haplo-HSCT in aggressive/refractory NHL A-K Zoellner et al improved over time in 55% of our patients who had achieved PR on day +30, while reaching CR during the next 2 months after haplo-HSCT. Similar observations of prolonged induction of remission after HLA-matched allogeneic HSCT were made by Wondergerm et al., 32 but in this study patients with less aggressive disease characteristics (all chemo-sensitive; 50% diagnosis of B-CLL or indolent B-cell lymphoma) were analysed. However, DLI could induce a temporary or permanent remission in four out of five of their relapsed patients. 32 There is little experience with DLI in the HLA-haploidentical setting, but feasibility and some efficacy in relapse post T-cell-replete haplo-HSCT has been observed. 39 We were able to perform DLI in two of our relapsed patients. A response was induced in both, while no severe GVHD occurred. Our observations suggest that there is a remarkable GVL reaction mediated by HLA-haploidentical transplantation in aggressive, non-remission and refractory NHL, while sequential therapy can provide enough time for it to come into play.
Outcomes of our high-risk cohort including refractory patients with active diseases at transplant are encouraging. This is reflected by a PFS of 56.2 and 50% after 1 and 2 years, respectively, from haplo-HSCT, while OS was 68.8% each. Outcomes compare favourably with those of patients with chemo-refractory/relapsed disease 40, 41 and aggressive lymphoma 3 undergoing RIC HLAmatched transplantation. Information about the outcome of chemo-refractory patients after allo-HSCT is rare. Gopal et al. 24 reported a prospective study on 40 patients (85% chemorefractory) with persistent indolent and aggressive B-cell lymphoma receiving a regimen with Y-Ibritumomab tiuxetan, fludarabine and TBI-based non-myeloablative conditioning in preparation for HLA-matched transplantation. They observed a comparatively lower PFS after 2 years (31%), whereas for the subgroup of DLBCL and MCL they report exclusively on a 6-month PFS (50 and 43%, respectively). This is similar to our cohort, but is confirmed on our study 1 and 2 years after sequential therapy. Recently, Glass et al. 42 reported on the results of a German randomized phase II study in the treatment of 86 patients with aggressive B-and T-cell lymphoma who had been refractory in 55% at the time of most frequently HLA-matched transplant. After myeloablative conditioning with fludarabine, BU and CY 1-year PFS was slightly lower (45%), while NRM was 35%.
In summary, our data suggest that sequential therapy combining clofarabine and T-cell-replete haplo-HSCT utilizing high-dose CY post transplant is feasible, well-tolerated and provides high anti-lymphoma activity, producing a remarkable benefit in the treatment of aggressive, non-remission NHL. It may allow enough time for the presumed GVL effect of haplo-HSCT, even in chemorefractory disease. Regarding the usually dismal prognosis of the selected patients, these promising results necessitate further investigation. 
